TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06133881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prilocaine
Description: intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
Study: NCT05066126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed-Presentation of Content
Description: Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
Study: NCT05983835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients receive subsegmentectomy
Description: Patients receive lobectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patients receive subsegmentectomy
Description: Patients receive lobectomy
Study: NCT05066126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed-Presentation of Content
Description: Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed-Presentation of Content
Description: Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed-Presentation of Content
Description: Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
Study: NCT05802277

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hamstring muscles function assessment
Description: Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring muscles function assessment
Description: Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
Study: NCT06016322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Chicory Root
Description: Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose).
Study: NCT02065323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADT
Description: Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard ADT
Description: Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
Study: NCT04833179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal transplant
Description: Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05294393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: N/S 0.9%
Description: 12 ml N/S 0.9% at the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 10%
Description: 12 ml solution of 100mg ropivacaine at the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10% plus magnesium sulphate 10mg/kg
Description: 12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
Study: NCT04617899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravascular imaging
Description: Use of imaging catheter
Study: NCT05504577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Study: NCT05290662

Intervention type: DRUG
Intervention: oNKord®
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells

Intervention type: DRUG
Intervention: Cyclophosphamide/Fludarabine (Cy/Flu)
Description: Lymphodepleting conditioning regimen
Study: NCT04847440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
Study: NCT05504577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Study: NCT05236322

Intervention type: DEVICE
Intervention: soft tissue laser
Description: Surgical laser used in excision purpose
Study: NCT05504577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apply the QCG
Description: apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: apply surgical gauze
Description: apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
Study: NCT04011800

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein isolation, or additional left or right-sided atrial lesions.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Risk Factor Modification
Description: dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
Study: NCT05394610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sana Device
Description: Audio Visual Stimulation patterns intended to produce a therapeutic benefit.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sana Device (Control)
Description: A control device that mimics the physcial appearance of the Sana device.
Study: NCT05975346

Intervention type: DRUG
Intervention: Ketamine
Description: description

Intervention type: OTHER
Intervention: saline nebulization
Description: description
Study: NCT04636567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerindocianine for injection
Description: Procedure: routine minimally invasive abdominopelvic surgery.
Study: NCT06151470

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha-Agonist
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: OTHER
Intervention: α-adrenergic receptor agonist
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT03814928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregivers eCourse
Description: Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
Study: NCT05064046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LuCa + Health Disparity module
Description: The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LuCa + Health Disparity module
Description: The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making.
Study: NCT06107543

Intervention type: DRUG
Intervention: Nebulized Lidocaine
Description: Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.

Intervention type: DRUG
Intervention: Iv Lidocaine
Description: Intravenous %2 lidocaine was administered before induction of anesthesia.
Study: NCT06000488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective Writing Workshop Sessions
Description: Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
Study: NCT06405295

Intervention type: OTHER
Intervention: no intervention
Description: Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention

Intervention type: OTHER
Intervention: no intervention
Description: Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
Study: NCT05738772

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sample for ELIZA
Description: Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sample for ELIZA
Description: Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
Study: NCT06089070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Continuous Glucose Monitor System
Description: Continuous Glucose Monitor System for people with Type 2 Diabetes
Study: NCT06206902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: After preconditioning with chemotherapy, F01 will be evaluated.
Description: Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
Study: NCT05269472

Intervention type: PROCEDURE
Intervention: Trigeminal Electrophysiology
Description: This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
Study: NCT05445882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BN-Brachyury
Description: BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
Study: NCT05323487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide Injection
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide Injection
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide Injection
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide Injection
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
Study: NCT06283992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Navigation
Description: 1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
Study: NCT05035095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive a daily dose of oral semaglutide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
Study: NCT05576610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)
Description: The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )
Description: The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures.
Study: NCT06447571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Rehabilitation
Description: Activating and strengthening the trunk muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability
Description: Standard core stability fucus on lower trunk.
Study: NCT06092632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pigmented rice
Description: Cooked black rice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Rice
Description: Cooked white rice
Study: NCT05992168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent-Retriever
Description: all the participants in this group will be performed with Stent-Retriever
Study: NCT06405295

Intervention type: OTHER
Intervention: no intervention
Description: Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
Study: NCT05955157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
Description: DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur Only Product
Description: Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur Only Product
Description: Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
Study: NCT05400356

Intervention type: PROCEDURE
Intervention: On-pump valve surgery or CABG
Description: On-pump valve surgery or coronary arterial bypass grafting

Intervention type: PROCEDURE
Intervention: On-pump valve surgery or CABG
Description: On-pump valve surgery or coronary arterial bypass grafting
Study: NCT06063512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sweet orange oil inhalation
Description: sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
Study: NCT05149612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Therapy
Description: Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
Study: NCT05073627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Description: Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.